Monitor for BLA submission in H1 2027 and FDA acceptance/priority review. The AZURE-1 and AZURE-4 data package will be key for regulatory approval; any safety or efficacy concerns in the full dataset could affect the timeline. Also watch for potential partnership or commercialization updates.
Drug in focus
MIRM drug pipeline →brelovitug
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3 (completed)
- Time to market
- Mirum plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2027, supported by the positive AZURE-1 and AZURE-4 results. If accepted and approved, commercial launch could follow in late 2027 or early 2027.
- Next catalyst
- BLA filing · H1 2027
What to watchBrelovitug has cleared its two pivotal Phase 3 trials (AZURE-1 and AZURE-4), setting up a BLA submission in H1 2027. The stock already reflects significant optimism (analyst mean target $155 vs ~$94 close), and the next major binary event is the BLA acceptance and subsequent FDA review. Watch for the AZURE-2 head-to-head data against Gilead's Hepcludex, which will determine brelovitug's commercial positioning in a market with one existing approved therapy.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $94.42entry
- T+1 · 6d ago +0.20%α −1.12% · $94.61
- T+4 · todayOpen
- T+5 · in 6h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Mirum announced that its Phase 3 AZURE-4 study for brelovitug in chronic hepatitis delta virus (HDV) met the primary endpoint at Week 24, with 59% (300 mg QW) and 44% (900 mg Q4W) of patients achieving virologic response and ALT normalization versus 0% in the delayed-treatment arm (p<0.0001). This is the second positive Phase 3 study for brelovitug, supporting a planned BLA submission in H1 2027 with a potential U.S. launch in Q4 2027. The data also showed deepening viral suppression and ALT normalization with longer treatment, including in patients with advanced cirrhosis.
Key Facts
- AZURE-4 Phase 3 study met primary endpoint at Week 24: 59% (300 mg QW) and 44% (900 mg Q4W) achieved combined virologic response and ALT normalization vs 0% in delayed-treatment arm (p<0.0001 for both)
- AZURE-4 is the second of two Phase 3 studies forming the U.S. registration package for brelovitug
- Company plans to submit BLA to FDA in first half of 2027, with potential U.S. commercial launch in Q4 2027 if approved
- Long-term data (up to 108 weeks) showed deepening viral suppression, increased ALT normalization, and improvements in liver stiffness
- No new safety signals; most common adverse event was flu-like illness (17.2%-18.5%), low injection site reactions (1.7%-7.4%)
- Study enrolled 113 treatment-naive patients, 53% with cirrhosis, mean baseline ALT 122 U/L
Financial Impact
No financial figures disclosed; brelovitug is an investigational asset with no approved revenue. Positive Phase 3 data supports regulatory filing and potential future revenue from HDV treatment.
Risk Factors
- BLA submission and FDA approval are not guaranteed; regulatory review may require additional data or raise safety/efficacy questions
- Commercial launch is contingent on approval and market acceptance; HDV is a niche indication with limited patient population
- Competing therapies in development for HDV could affect market share if brelovitug is approved
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759425-26-000064 |
| Document: 0001759425-26-000064-index-headers.html | 0001759425-26-000064 |
| Document: 0001759425-26-000064-index.html | 0001759425-26-000064 |
| Document: 0001759425-26-000064.txt | 0001759425-26-000064 |
Track record
27 reports on MIRM
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
- Nov 10, 20266d ago 8-K Bullish 6/10 Viewing Entry $94.42 Now $91.58 −3.01% settles Feb 8
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers